Navigation Links
R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection
Date:10/24/2007

ges in hematologic or other laboratory parameters.

Part 3 is a multi-center, observer-blinded, within-cohort randomized, placebo-controlled study being conducted in up to 75 treatment-naive patients with genotype 1 hepatitis C virus. The primary objective is to assess the safety, tolerability and pharmacokinetics of R7128 in combination with Pegasys plus Copegus. The secondary objective of Part 3 is to evaluate the short-term change in HCV RNA. The study will include two to three oral doses of R7128 (500 mg to 1500 mg) that are being administered twice-daily with Pegasys plus Copegus for 28 days.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and is a leading cause of chronic liver disease and liver transplants. The WHO estimates that nearly 180 million people worldwide, or approximately 3% of the world's population, are infected with hepatitis C virus (HCV). The CDC has reported that almost four million people in the United States have been infected with HCV, of whom 2.7 million are chronically infected.

Contact

Alan Roemer, Vice President

Investor Relations & Corporate Communications

alan.roemer@pharmasset.com

Office: (609) 613-4125

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation the risk that the FDA withdraws the R7128 fast track designation, the risk that the FDA does not expedite the review or approval of any application for R7128, the risk that adverse events could cause the cessation of the Phase 1 study and/or our development of R7128, the risk that our collaboration with Roche will not continue or
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
4. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
5. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Stanford Researchers Track Human Stem Cells Transplanted Into Rat Brain
8. Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
9. Staphylococcus aureus vaccine development on track ? safe and immunogenic in Phase I clinicaltrials
10. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
11. Point of Care Strep Tests Speed Treatment, Lower Costs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 5, 2015 WuXi PharmaTech (Cayman) Inc. (NYSE: ... and technology platform company serving the pharmaceutical, biotechnology, and ... United States, today announced its financial results for the ... Fourth-Quarter 2014 Highlights , Net Revenues Increased 21.3% ... Services Net Revenues Grew 17.7% Year Over Year to ...
(Date:3/5/2015)... Deutschland, 5. März 2015  Die amerikanische ... deutsche biopharmazeutische Unternehmen CureVac geben heute bekannt, ... Millionen US-Dollar) in CureVac investiert. CureVac ist ... Messenger-RNA (mRNA). Auf Basis dieses Moleküls entwickelt ... Krankheiten und zum Schutz vor Infektionskrankheiten. ...
(Date:3/5/2015)... , March 5, 2015  BioPhotas, Inc., an FDA ... use patented photo-therapeutic technologies to treat skin, muscle and ... the Semper Fi Fund to provide BioPhotas, flagship product, ... of pain management solutions.  Commenting on ... Marine who used the Celluma at the Warrior Hope ...
Breaking Medicine Technology:WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 20WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 21WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 22Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 2Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 3Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 4BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 2BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 3
... Help Survivors Start Exercise Routine Based on Current Cardiovascular ... of cancer survivors is not affected by many standard ... Medical Cancer. That is the finding of a ... American College of Sports Medicine in Seattle. "We ...
... Progression-Free Survival, Disease Control and Neurotoxicity Data To ... to Support Picoplatin as a Neuropathy-Sparing Alternative to ... Poniard Management Team to Host Analyst and Investor ... - SOUTH SAN FRANCISCO, Calif., May 28 ...
Cached Medicine Technology:Cardiovascular Fitness Not Affected by Cancer Treatment 2Cardiovascular Fitness Not Affected by Cancer Treatment 3Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 2Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 3Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 4Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 5Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer 6
(Date:3/5/2015)... 2015 Shania Twain will be touring ... decade. She has hinted that this will be her final ... perform one last time. She has had a residency in ... sweetheart has millions of loyal fans around the world. After ... Canada, and on June 30th she will be at Madison Square ...
(Date:3/5/2015)... York, New York (PRWEB) March 05, 2015 ... of men who allegedly suffered heart attacks, strokes and ... prescription low testosterone therapies continue to move forward in ... Court, Northern District of Illinois. According to a Case ... set forth procedures for the use of master pleadings ...
(Date:3/5/2015)... Los Angeles, CA (PRWEB) March 05, 2015 ... online article titled “Butt Augmentation, Labiaplasty on the Rise, ... surveys reported by the American Society for Aesthetic ... Plastic Surgeons . Both groups reported a year-over-year doubling ... one of the physicians quoted in the article, this ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 ... in healthcare communications and education, announced today its ... (AMP), the nation’s only medical conference designed for ... ischemia and lower limb amputation due to vascular ... family of innovative, evidence-based publications and CME activities ...
(Date:3/5/2015)... Venice, FL (PRWEB) March 05, 2015 ... their 15th annual listing of “Pros to Know” in ... announce that two members of MEBC’s leadership team were ... Rhodes were nominated and received this award due to ... use of innovative methods for meeting and resolving client ...
Breaking Medicine News(10 mins):Health News:Shania Twain Tickets: Ticket Down Announces Shania Twain's 2015 “Rock This Country” North American Tour 2Health News:Shania Twain Tickets: Ticket Down Announces Shania Twain's 2015 “Rock This Country” North American Tour 3Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 2Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 3Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 4Health News:The Kim Kardashian and Jennifer Lopez Effect: Butt Augmentations Double from 2013 to 2014 2Health News:HMP Holdings Acquires The Amputation Prevention Symposium (AMP) 2Health News:HMP Holdings Acquires The Amputation Prevention Symposium (AMP) 3Health News:MEBC Leaders Awarded Supply Demand Chain Executive Pros to Know Title For 2015 2
... ... back to a six year success story as a national retailer for ... since 2004 more and more requests have been received from nearly all ... and more shipped to the UK, USA and even Australia.,Strandkorb & Meer ...
... the Gulf of Mexico, and they are concerned about its potential ... from a continuing survey conducted by the University of Minnesota. ... conducted by The Food Industry Center at the U of M. ... were aware of the spill and 85 percent say they are ...
... drugs using gas bubbles and sound waves is to be ... highly toxic drugs to be delivered in small doses directly ... good use. If successful, the technique could easily be adapted ... chemists and cancer specialists from across the University to work ...
... the University of Kentucky,s College of Medicine have identified ... risk for Alzheimer,s disease that could prove important for ... by Brian Gold, associate professor of anatomy and neurobiology, ... majority of deep parts of the brain and consists ...
... Monday, June 28, 2010 In the first ever published ... live with their minor children, a team led by a ... of cancer survivors are parenting young children, highlighting a group ... today in Cancer , a peer-reviewed journal of the ...
... the University of Leicester have demonstrated that movable sequences of ... specific diseases, are far more common than previously thought. ... , Dr Richard Badge and his collaborators examined L1 (or ... genetic code around the genome. By breaking up genes, L1s ...
Cached Medicine News:Health News:Strandkorb & Meer Going to Exceed 20% of Total Sales Volume with International Business in 2010 2Health News:Strandkorb & Meer Going to Exceed 20% of Total Sales Volume with International Business in 2010 3Health News:Bursting bubbles with sound offers new treatments for cancer 2Health News:Bursting bubbles with sound offers new treatments for cancer 3Health News:Alzheimer's imaging study identifies changes in brain's white matter 2Health News:More than a million parents with minor children are cancer survivors 2Health News:'Copy-and-paste DNA' more common than previously thought 2
... Cortisol Range Verifiers have been validated for ... Immunodiagnostic Products Cortisol Reagent Pack and Vitros,Immunodiagnostic ... low and,high cortisol concentrations, close to the ... be used,to verify measurement of cortisol at ...
Rapid assay, results in 1 hours,Range 20-800 ng/mL; sensitivity 2.5 ng/mL,Can be used for animal sera; requires extraction protocol and steroid free serum...
... 1000 assays are designed for ... IMMULITE 1000, continuous random access ... in both design and operation. ... in a wide variety of ...
... XCAT 100 X-Ray System from KUBTEC is a ... two and three dimensional representation of the specimen ... reconstruction of specimen X-ray images, the micro focus ... level of detail in standard 2D images. The ...
Medicine Products: